Bolt Biotherapeutics Inc.

6 trials 1 recruiting Commercial sponsor Merged from 4 name variants

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

3 Completed trials

10 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 1 Phase II: 2 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

Oversight events:

8 temporary halts across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Dry age-related macular degeneration 1 HER2 protein overexpression 1

Top IMPs

BDC-1001 2 BALSTILIMAB 1 ELAMIPRETIDE TRIHYDROCHLORIDE 1 GEMCITABINE 1 HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST CLDN6 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A CATHEPSIN HYDROLYSABLE DIPEPTIDE VC LINKER 1 NIVOLUMAB 1 OBEROTATUG RAVTANSINE 1

All trials

6 total

A Phase 1 Study of TORL-1-23 in Advanced Cancer Pending

2024-517189-40-00 Phase I 1 country
Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting

2024-511884-27-00 Phase I (Other) 4 countries BALSTILIMAB; GEMCITABINE; OBEROTATUG RAVTANSINE
ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Sub… Ended

2024-511482-11-00 Phase III 5 countries ELAMIPRETIDE TRIHYDROCHLORIDE
CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Halted

2024-517190-24-00 Phase II 8 countries HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST CLDN6 CONJUGATED TO MONOMETHYL AURIST…
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos… Ended

2023-506038-65-00 Phase II 3 countries BDC-1001
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors Ended

2024-518411-19-00 Phase I/II 1 country BDC-1001; NIVOLUMAB

Showing 1–6 of 6 trials

← All sponsors A–Z